Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aflac Incorporated stock logo
AFL
Aflac
$114.79
-0.3%		$121.39
$105.43
▼
$130.22
$57.55B0.592.33 million shs1.75 million shs
LGN stock logo
LGN
LGN
$55.22
-3.2%		$64.64
$26.96
▼
$107.24
$5.97BN/A1.42 million shs525,151 shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$288.05
-0.3%		$296.73
$161.82
▼
$326.63
$5.74B1.11271,225 shs309,961 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aflac Incorporated stock logo
AFL
Aflac
-1.62%-0.55%-7.58%-1.57%+8.25%
LGN stock logo
LGN
LGN
+7.68%+10.54%-11.35%-29.31%+5,703,999,900.00%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
+1.13%+1.60%-1.47%+16.35%+74.14%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aflac Incorporated stock logo
AFL
Aflac
$114.79
-0.3%		$121.39
$105.43
▼
$130.22
$57.55B0.592.33 million shs1.75 million shs
LGN stock logo
LGN
LGN
$55.22
-3.2%		$64.64
$26.96
▼
$107.24
$5.97BN/A1.42 million shs525,151 shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$288.05
-0.3%		$296.73
$161.82
▼
$326.63
$5.74B1.11271,225 shs309,961 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aflac Incorporated stock logo
AFL
Aflac
-1.62%-0.55%-7.58%-1.57%+8.25%
LGN stock logo
LGN
LGN
+7.68%+10.54%-11.35%-29.31%+5,703,999,900.00%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
+1.13%+1.60%-1.47%+16.35%+74.14%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aflac Incorporated stock logo
AFL
Aflac
2.21
Hold$116.621.59% Upside
LGN stock logo
LGN
LGN
2.93
Moderate Buy$99.5080.19% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
3.00
Buy$335.7516.56% Upside

Current Analyst Ratings Breakdown

Latest AFL, LGN, and LGND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/31/2026
LGN stock logo
LGN
LGN
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D)
8/21/2026
Aflac Incorporated stock logo
AFL
Aflac
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B+) ➝ Buy (A-)
8/19/2026
Aflac Incorporated stock logo
AFL
Aflac
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetEqual Weight$120.00 ➝ $122.00
8/19/2026
Aflac Incorporated stock logo
AFL
Aflac
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageUnderperform$103.00
8/19/2026
Aflac Incorporated stock logo
AFL
Aflac
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageUnderperform$103.00
8/19/2026
LGN stock logo
LGN
LGN
Tigress Financial logo
Tigress Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$125.00 ➝ $130.00
8/18/2026
LGN stock logo
LGN
LGN
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$115.00
8/17/2026
LGN stock logo
LGN
LGN
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/14/2026
LGN stock logo
LGN
LGN
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D+)
8/14/2026
LGN stock logo
LGN
LGN
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$105.00 ➝ $116.00
8/14/2026
LGN stock logo
LGN
LGN
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$100.00 ➝ $105.00
(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aflac Incorporated stock logo
AFL
Aflac
$17.16B3.35$9.13 per share12.58$56.27 per share2.04
LGN stock logo
LGN
LGN
$3.75B1.59$0.65 per share85.28$7.49 per share7.37
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$290.54M19.77$7.92 per share36.37$51.68 per share5.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aflac Incorporated stock logo
AFL
Aflac
$3.65B$9.3312.3015.011.8926.91%13.27%3.34%11/4/2026 (Estimated)
LGN stock logo
LGN
LGN
-$59.78M$0.40138.0523.20N/A-1.20%4.33%1.23%N/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$124.45M$9.3530.8134.792.2967.88%20.06%11.68%11/5/2026 (Estimated)

Latest AFL, LGN, and LGND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
LGN stock logo
LGN
LGN
$0.26-$0.37-$0.63-$0.37N/A$1.26 billion
8/6/2026Q2 2026
Aflac Incorporated stock logo
AFL
Aflac
$1.76$1.75-$0.01$1.63$4.11 billion$4.22 billion
8/6/2026Q2 2026
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.97$2.37+$0.40$2.22$61.30 million$63.69 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aflac Incorporated stock logo
AFL
Aflac
$2.442.13%+15.68%26.15%44 Years
LGN stock logo
LGN
LGN
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A

Latest AFL, LGN, and LGND Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/6/2026
Aflac Incorporated stock logo
AFL
Aflac
quarterly$0.612.09%8/19/20268/19/20269/1/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aflac Incorporated stock logo
AFL
Aflac
0.29
0.12
0.12
LGN stock logo
LGN
LGN
1.03
1.35
1.35
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
1.16
31.18
30.96

Institutional Ownership

CompanyInstitutional Ownership
Aflac Incorporated stock logo
AFL
Aflac
67.44%
LGN stock logo
LGN
LGN
N/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
91.28%

Insider Ownership

CompanyInsider Ownership
Aflac Incorporated stock logo
AFL
Aflac
0.80%
LGN stock logo
LGN
LGN
0.01%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
5.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aflac Incorporated stock logo
AFL
Aflac
12,716501.34 million497.33 millionOptionable
LGN stock logo
LGN
LGN
7,000108.08 million108.06 millionN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
8019.94 million18.82 millionOptionable

Recent News About These Companies

Ligand Pharmaceuticals (NASDAQ:LGND) Insider Andrew Reardon Sells 5,000 Shares
September 9 at 4:21 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-lgnd-insider-buying-and-selling-2026-09-09/
4,000 Shares in Ligand Pharmaceuticals Incorporated $LGND Acquired by JW Asset Management LLC
September 8 at 7:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-4000-shares-in-ligand-pharmaceuticals-incorporated-lgnd-acquired-by-jw-asset-management-llc-2026-09-08/
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Insider Sells 5,000 Shares of Stock
September 8 at 7:07 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-ligand-pharmaceuticals-nasdaq-lgnd-insider-sells-5000-shares-of-stock-2026-09-08/
TD Waterhouse Canada Inc. Buys New Shares in Ligand Pharmaceuticals Incorporated $LGND
September 7 at 5:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-td-waterhouse-canada-inc-buys-new-shares-in-ligand-pharmaceuticals-incorporated-lgnd-2026-09-07/
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Rating of "Buy" from Brokerages
September 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31000057
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Buy" by Brokerages
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-ligand-pharmaceuticals-incorporated-nasdaq-lgnd-given-consensus-recommendation-of-buy-by-brokerages-2026-09-03/
Bank of New York Mellon Corp Purchases New Holdings in Ligand Pharmaceuticals Incorporated $LGND
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-purchases-new-holdings-in-ligand-pharmaceuticals-incorporated-lgnd-2026-08-29/
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-ligand-pharmaceuticals-highlights-xoma-fueled-royalty-growth-700m-in-deployable-capital-2026-08-26/
Ligand to Participate in September Investor Conferences
August 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/26/3351186/0/en/ligand-to-participate-in-september-investor-conferences.html
Ranger Investment Management L.P. Acquires Shares of 257,596 Ligand Pharmaceuticals Incorporated $LGND
August 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-ranger-investment-management-lp-acquires-shares-of-257596-ligand-pharmaceuticals-incorporated-lgnd-2026-08-24/
Craig-Hallum Keeps Their Buy Rating on Ligand Pharma (LGND)
August 20, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/LGND/pressreleases/3736873/craig-hallum-keeps-their-buy-rating-on-ligand-pharma-lgnd/
Ligand Pharma (LGND) Gets a Buy from Oppenheimer
August 20, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/LGND/pressreleases/3736212/ligand-pharma-lgnd-gets-a-buy-from-oppenheimer/
Ligand Pharmaceuticals Earnings Call Signals Royalty-Driven Surge
August 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ligand-pharmaceuticals-earnings-call-signals-royalty-driven-surge?utm_source=marketbeat.com&utm_medium=referral
Bank of America Corp DE Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND
August 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-raises-holdings-in-ligand-pharmaceuticals-incorporated-lgnd-2026-08-16/
Jason Haas Sells 7,138 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) Stock
August 15, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-lgnd-insider-buying-and-selling-2026-08-15/
Ligand Pharmaceuticals (NASDAQ:LGND) Director Jason Haas Sells 7,138 Shares
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ligand-pharmaceuticals-nasdaqlgnd-director-jason-haas-sells-7138-shares-2026-08-14/
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells 31,641 Shares of Stock
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-selling-ligand-pharmaceuticals-nasdaqlgnd-cfo-sells-31641-shares-of-stock-2026-08-14/
Ligand Pharmaceuticals (NASDAQ:LGND) Now Covered by Leerink Partners
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/ligand-pharmaceuticals-nasdaqlgnd-now-covered-by-leerink-partners-2026-08-14/
Breakout watch: Savvy investors bet millions on royalty-fueled pharma stock
August 13, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/breakout-watch-savvy-investors-bet-millions-on-royalty-fueled-pharma-stock/ar-AA2a1hZI
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), AMN Healthcare Services (AMN) and Warby Parker (WRBY)
August 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/AMN/pressreleases/3739538/analysts-offer-insights-on-healthcare-companies-ligand-pharma-lgnd-amn-healthcare-services-amn-and-warby-parker-wrby/
Ligand Pharmaceuticals Incorporated (LGND) Q2 2026 Earnings Call Transcript
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932313-ligand-pharmaceuticals-incorporated-lgnd-q2-2026-earnings-call-transcript

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aflac stock logo

Aflac NYSE:AFL

$114.79 -0.37 (-0.32%)
Closing price 03:59 PM Eastern
Extended Trading
$114.77 -0.02 (-0.02%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan. The Aflac U.S. segment provides cancer, accident, short-term disability, critical illness, hospital indemnity, dental, vision, long-term care and disability, and term and whole life insurance products in the United States. It sells its products through sales associates, brokers, independent corporate agencies, individual agencies, and affiliated corporate agencies. Aflac Incorporated was founded in 1955 and is headquartered in Columbus, Georgia.

LGN stock logo

LGN NASDAQ:LGN

$55.22 -1.82 (-3.19%)
Closing price 04:00 PM Eastern
Extended Trading
$56.00 +0.78 (+1.41%)
As of 05:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Legence Corp. is a provider of engineering, consulting, installation and maintenance services for mission-critical systems in buildings. The company specializes in designing, fabricating and installing complex HVAC, process piping and other mechanical, electrical and plumbing systems. Legence Corp. is based in SAN JOSE, Calif.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$288.05 -0.78 (-0.27%)
Closing price 04:00 PM Eastern
Extended Trading
$288.06 +0.00 (+0.00%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas